The findings? Zepbound led to an average weightloss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these ...
Zepbound helps aid weightloss. Research consistently suggests people with overweight or obesity have more average weightloss on Zepbound than a placebo. The active ingredient in ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weightloss is most effective at helping people lose more weight in less time.